Home | Register | Login | Inquiries | Alerts | Sitemap |  

Advanced Search
JKM > Volume 41(3); 2020 > Article
Kim: A clinical literature review and research-trends analysis of bee venom pharmacopuncture for cancer patients



This review aims to investigate clinical studies related to bee venom pharmacopuncture for cancer patients and to analyze the research trend for further study.


We searched for clinical studies using bee venom pharmacopuncture therapy on patients with cancer through the electronic databases including Pubmed, Cochrane library, OASIS, KISS, NDSL, and KMBASE. There was no restriction on language and publication date, and after selection/exclusion process, the study design, target disease, intervention details including acupoints, treatment frequency and period, outcomes, study results and adverse events were extracted.


Thirteen clinical studies were finally selected. There were a randomized controlled trial RCT about the effect of sweet bee venom pharmacopuncture on cancer-related pain, and three case series about chemotherapy-induced peripheral neuropathy. In case reports, there were nine studies about oligodendroglioma, plexiform neurofibroma, breast cancer, prostate cancer, lung cancer, urachal adenocarcinoma, malignant melanoma, and atypical squamous cells of undetermined significance. The bee venom therapy affected the improvement of outcomes such as symptoms, quality of life, tumor response, and lab findings.


The present study found that bee venom therapy is applicable to the treatment of cancer patients, and showed some effect on various symptoms. However, due to insufficient number and quality of studies, well designed and high-quality clinical trials are necessary to confirm the effectiveness and safety of bee venom pharmacopuncture therapy in patients with cancer.


This research was supported by Sangji University Research Fund, 2018. I thanks to my medical student Hyeon-Jong Yoo for performing study selection and data extraction.

Fig. 1
Study flow chart
Table 1
Characteristics of the Included Studies
Author, year Study design Patients (n) Interventions (n) Acupoint/Dosage Frequency of Treatment Concomitant treatment Outcomes Results Adverse events (n)
Yoo et al., 200830) RCT Patients with cancer-related pain (11) TG: SBV (6), 0.1mg/ml
CG: Placebo (5), normal saline
CV12/1ml daily for five days - 1. NRS
1) immediate pain relief
2) long term
1) T>C (p<0.05)
2) NS
Kim et al., 201831) Case report Breast cancer patient with chemotherapy-induced Side effects (1) nBV ST36, ST35, ST34, GB34, Ashi/0.2–0.4cc each point 3 times/week, total 10 session AT, MT, HM
Improved NR
Kim et al., 2015 41) Case report Oligodendroglioma (1) BV GV20, EX-HN1/0.2 mL each point once weekly for 18 months ATX, HM, PA(MG) 1. Tumor size (Brain MRI)
2. Symptoms
3. Survival
1. decreased markedly
2. improved symptoms
Lim et al., 201433) Case report Plexiform neurofibroma (1) SBV, intracutaneously the borders of the PNFs/5 mL every two weeks for 4 years PA(MG) 1. Tumor response (MRI)
2. Symptoms (hip joint pain, ROM)
1. the growths of the PNFs have almost stopped
2. improved symptoms
Park et al., 201432) Case series CIPN (4) BV, Ointment Hand and/or foot 1–2 times/day - 1. VAS 1. improved None
Yoon et al., 201234) Case series CIPN (11) SBV, 0.1 cun LI4, TE5, GB39, LR3/0.1 ml each point Total 6 session for 3 weeks - 1. WHO grading system,
2. PNQ
3. VAS
1. improved (p<0.01)
2. improved (p<0.05)
3. improved (p<0.01)
1. improved (p<0.01)
swelling and itchiness at the injection site (1)
mild fever (1)
Park et al., 201240) Case series CIPN (5) SBV, Melittin of 0.1 mg/mL, 0.1 cm EX-LE10, EX-UE9/0.1 ml each point 3 sessions over a 1-week period - 1. VAS: pain
2. WHO CIPN grade
1. improved: 8.75 –> 2.75
2. improved: 2.5–>1
3. improvedin physical section: 10.5–>18.5
Lee et al., 201142) Case report Prostate cancer patients (2) SBV CV12, CV6/0.3ml each point, LI4, LR3, ST36, CV3, SP6, CV1/0.1 ml each point 2–5 times/week AT, PA(MG) 1. PSA 1. decreased NR
Gu et al., 201143) Case report Lung Cancer Patient (1) SBV, 10% BL13, Ashi/0.4–0.6ml 3 times/week AT, MT, cupping, HM, breathing meditation 1. BDI
3. BAI
4. ASI
1. decreased
2. decreased
3. decreased
4. decreased
Choi et al., 201144) Case report Urachal Adenocarcinoma Patient (1) SBV LI4, LR3/0.1ml each point, BL20, BL21/0.25ml each point 2–3 times/week AT, HM 1. Symptoms
2. Lab finding
1. Stable
2. Stable
Park et al., 201045) Case report lung adenocarcinoma (1) BV CV12, GV3 every 2 days AT, MT, cupping, HM, PA(placenta), Massage, TENS, Hydrotherapy (hip bath and foot bath), meditation, exercise 1. Symptoms: exertional dyspnea with thoracic pain and pain in both upper limbs, emotional stress 1. improved disease-free survival of 28 months NR
Bang et al., 200746) Case report Malignant melanoma (1) BV, 10000:1 Lesion, 1.5ml Once a day for 1 year - 1. Tumor response (PET CT, Neck CT) 1. Stable disease None
Kim et al., 200547) Case report ASCUS (2) BV Lesion, SC 0.2–0.6ml Once a week, total 12 session - 1. Pap smear
2. HPV test
3. Cervical biopsy
1. negative
2. negative
(1) Immature metaplasia→Squamous metaplasia
(2) Squamous metaplasia→Koilocytotic change

SBV, Sweet Bee Venom; NRS, Numerical Rating Scale; NR, not reported; NS, non-statistically significant; nBV, non-toxic Bee Venom; CWG, Cultivated Wild Ginseng; TC, Trionycis Carapax; Common Toxicity Criteria for Adverse Event, CTCAE; ECOG, Eastern Cooperative Oncology Group; MG, mountain ginseng; ROM, range of motion; CIPN, chemotherapy-induced peripheral neuropathy; PNQ, Patient Neurotoxicity Questionnaire; HRQOL, Health-Related Quality of Life; FACT-G, Functional Assessment of Cancer Therapy-General; PSA, Prostate specific antigen; BDI, Beck’s depression inventory; HRSD, Hamilton rating scale for depression; BAI, Beck’s anxiety inventory; ASI, Anxiety status inventory; ASCUS, Atypical squamous cells of undetermined significance; HPV, human papilloma virus; SC, subcutaneous; AT, acupuncture; HM, herbal medicine; MT: Moxibustion; PA, pharmacopuncture; TENS, Transcutaneous Electrical Nerve Stimulation,


1. National cancer information center. Cancer prevalence rates. Available from: URL: https://www.cancer.go.kr/lay1/S1T654C655/contents.do

2. Towler P, Molassiotis A, Brearley S. What is the evidence for the use of acupuncture as an intervention for symptom management in cancer supportive and palliative care: an integrative overview of reviews. Supportive Care in Cancer. 2013; 21:10. 2913–23.
crossref pmid

3. Bao T, Patil S, Chen C, Zhi IW, Li QS, Piulson L, et al. Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms: A Randomized Clinical Trial. JAMA Netw Open. 2020; 3:3. e200681
crossref pmid pmc

4. Garcia MK, Meng Z, Rosenthal DI, Shen Y, Chambers M, Yang P, et al. Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2019; 2:12. e1916910
crossref pmid pmc

5. Jin H, Xiang Y, Feng Y, Zhang Y, Liu S, Ruan S, et al. Effectiveness and Safety of Acupuncture Moxibustion Therapy Used in Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis. Evidence-based complementary and alternative medicine. eCAM. 2020; 2020:3237451.

6. Lu W, Giobbie-Hurder A, Freedman RA, Shin IH, Lin NU, Partridge AH, et al. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. The oncologist. 2020; 25:4. 310–8.
crossref pmid

7. Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, et al. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. Jama. 2018; 320:2. 167–76.
crossref pmid pmc

8. Park JM, You SJ, Choi SY, Moon G, Lyu YS. Survey of Motives for Visiting Oriental Medical Hospital and Satisfaction with Oriental Medical Care for Cancer Patients: Report of 22 Cases. J of Oriental Neuropsychiatry. 2015; 26:1. 23–38.

9. Committee KAMSTC. Acupuncture Medicine. Seoul: Hanmi medicine;2020.

10. Kim J, Kang DI. A descriptive statistical approach to the Korean pharmacopuncture therapy. J Acupunct Meridian Stud. 2010; 3:3. 141–9.
crossref pmid

11. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacology & therapeutics. 2007; 115:2. 246–70.
crossref pmid

12. Zheng J, Lee HL, Ham YW, Song HS, Song MJ, Hong JT. Anti-cancer effect of bee venom on colon cancer cell growth by activation of death receptors and inhibition of nuclear factor kappa B. Oncotarget. 2015; 6:42. 44437–51.
crossref pmid pmc

13. pSW , Liao SS, Lin SY, Lin JP, Yang JS, Lin ML, et al. The role of mitochondria in bee venom-induced apoptosis in human breast cancer MCF7 cells. In vivo (Athens, Greece). 2008; 22:2. 237–45.

14. Kim DH, Lee HW, Park HW, Lee HW, Chun KH. Bee venom inhibits the proliferation and migration of cervical-cancer cells in an HPV E6/E7-dependent manner. BMB reports. 2020.

15. Lee HL, Park SH, Kim TM, Jung YY, Park MH, Oh SH, et al. Bee venom inhibits growth of human cervical tumors in mice. Oncotarget. 2015; 6:9. 7280–92.

16. Kim YW, Chaturvedi PK, Chun SN, Lee YG, Ahn WS. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line. Oncology reports. 2015; 33:4. 1675–82.
crossref pmid

17. Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, et al. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicology and applied pharmacology. 2012; 258:1. 72–81.
crossref pmid

18. Han G, Shin H, Seong S, Kim S. Systematic Review of Case Reports about Korean Medicine for Lung Cancer. J Korean Med. 2018; 39:4. 136–57.

19. Jeong YJ, Park YY, Park KK, Choi YH, Kim CH, Chang YC. Bee Venom Suppresses EGF-Induced Epithelial-Mesenchymal Transition and Tumor Invasion in Lung Cancer Cells. The American journal of Chinese medicine. 2019; 47:8. 1869–83.
crossref pmid

20. Liu S, Yu M, He Y, Xiao L, Wang F, Song C, et al. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology. 2008; 47:6. 1964–73.
crossref pmid

21. Wang X, Li H, Lu X, Wen C, Huo Z, Shi M, et al. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Cell death & disease. 2018; 9:10. 940
crossref pmid

22. Park MH, Choi MS, Kwak DH, Oh KW, Yoon DY, Han SB, et al. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB. The Prostate. 2011; 71:8. 801–12.
crossref pmid

23. Ip SW, Chu YL, Yu CS, Chen PY, Ho HC, Yang JS, et al. Bee venom induces apoptosis through intracellular Ca2+-modulated intrinsic death pathway in human bladder cancer cells. International journal of urology : official journal of the Japanese Urological Association. 2012; 19:1. 61–70.
crossref pmid

24. Ryu HK, Baek YH, Park YC, Seo BK. Current studies of acupuncture in cancer-induced bone pain animal models. Evidence-based complementary and alternative medicine : eCAM. 2014; 2014:191347.

25. Choi S, Chae HK, Heo H, Hahm DH, Kim W, Kim SK. Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats. Toxins. 2019; 11:7.

26. Yun HS, Lee JD, Lee YH. Systemic Review: The Study on Bee Venom Related to Cancer in PubMed. J Acupunct Res. 2000; 17:4. 69–78.

27. Han CH, Lee YS, Kwon OM, Lee YJ. The Review on the Study of Bee Venom in the Journals of Korean Medicine. Korean Journal of Acupuncture. 2013; 30:1. 27–36.

28. Han C, Lee Y, Sung S, Lee B, Shin H, Lee Y. Trend Analysis of the Research on Bee Venom Acupuncture in South Korea, Based on Published Articles. J Korean Med. 2015; 36:4. 80–103.

29. Cheon S, Zhang X, Lee IS, Cho SH, Chae Y, Lee H. Pharmacopuncture for cancer care: a systematic review. Evid Based Complement Alternat Med. 2014; 2014:12. 804746
crossref pmid pmc

30. Yoo H, Kim J. The Effect of Sweet Bee Venom Pharmacopuncture(SBVP) on Cancer -Related Pain : A Randomized Controlled Trial and Double Blinded - Pilot study. Journal of Pharmacopuncture. 2008; 11:1. 21–9.

31. Kim M, Jung Y, Hong S. A Case Report of Cyclophosphamide plus Doxorubicin-induced Side effects in Patient with Both Sides Breast Cancer Treated with Integrative Medicine Therapy Including Pharmacopuncture. J of Kor Traditional Oncology. 2018; 23:1. 33–43.

32. Park B, Kim J, Cho C, Shin S, Yoo H. Effect of Bee Venom Ointment Treatment for Chemotherapy-induced Peripheral Neuropathy : A Case Series. 2014; 22:2. 111–7.

33. Lim C, Kwon K, Lee K. Plexiform Neurofibroma Treated with Pharmacopuncture. Journal of Pharmacopuncture. 2014; 17:3. 74–7.

34. Yoon J, Jeon JH, Lee YW, Cho CK, Kwon KR, Shin JE, et al. Sweet Bee Venom Pharmacopuncture for Chemotherapy-Induced Peripheral Neuropathy. Journal of Acupuncture and Meridian Studies. 2012; 5:4. 156–65.
crossref pmid

35. Oršolić N. Bee venom in cancer therapy. Cancer and metastasis reviews. 2012; 31:1. 173–94.
crossref pmid

36. Ma R, Mahadevappa R, Kwok HF. Venom-based peptide therapy: insights into anti-cancer mechanism. Oncotarget. 2017; 8:59. 100908–30.
crossref pmid pmc

37. Park JH, Jeong YJ, Park KK, Cho HJ, Chung IK, Min KS, et al. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Molecules and cells. 2010; 29:2. 209–15.
crossref pmid

38. Cornara L, Biagi M, Xiao J, Burlando B. Therapeutic Properties of Bioactive Compounds from Different Honeybee Products. Frontiers in pharmacology. 2017; 8:412
crossref pmid pmc

39. Lazdunski M, Fosset M, Hughes M, Mourre C, Romey G. Schmid-Antomarchi H, The apamin-sensitive Ca2+-dependent K+ channel molecular properties, differentiation and endogenous ligands in mammalian brain. Biochemical Society symposium. 1985; 50:31–42.

40. Park JW, Jeon JH, Yoon J, Jung TY, Kwon KR, Cho CK, et al. Effects of sweet bee venom pharmacopuncture treatment for chemotherapy-induced peripheral neuropathy: a case series. Integrative cancer therapies. 2012; 11:2. 166–71.
crossref pmid

41. Kim JS, Lee HJ, Lee SH, Lee BH. Recurrent Oligodendroglioma Treated with Acupuncture and Pharmacopuncture. Journal of Acupuncture and Meridian Studies. 2015; 8:3. 147–51.
crossref pmid

42. Lee Y, Kim C, Lee K. A case report of monitoring PSA level changes in two prostate cancer patients treated with Mountain Ginseng Pharmacopuncture and Sweet Bee Venom along with western anticancer therapy. Journal of Pharmacopuncture. 2011; 14:4. 81–8.

43. Gu JH, Kim SR, Im EY, Kim SH, Kim JD. One Clinical Case Report of Lung Cancer Patient with Depression and Anxiety Disorder Improved by Korean Traditional Medical Treatment and Breathing Meditation. Korean J Oriental Physiology & Pathology. 2011; 25:6. 1102–7.

44. Choi J, Cho C, Lee Y, Yoo H. A Case of Urachal Adenocarcinoma Patient Treated with Oriental Medicine. J of Kor Traditional Oncology. 2011; 16:2. 53–61.

45. Park HM, Kim SY, Jung IC, Lee YW, Cho CK, Yoo HS. Integrative tumor board: a case report and discussion from East-West Cancer Center. Integr Cancer Ther. 2010; 9:2. 236–45.
crossref pmid

46. Bang SH, Yoo HS. A Case Report on the Patient of Malignant Melanoma at Right Maxilla with the Treatment of Bee Venom Phamacopuncture. Journal of Pharmacopuncture. 2007; 10:2. 99–105.

47. Kim SW, Zhang KH, Yi YJ, Kim BN, Kim SH. A report of Atypical squamous cells of undetermined significance(ASCUS) treated by Bee Venom Therapy. The Journal of Oriental Obstetrics & Gynecology. 2005; 18:2. 169–75.

Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-3627   Fax : +82-2-2658-3631   E-mail : skom1953.journal@gmail.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Developed in M2PI